drugset / Trial / NCT06685835

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT06685835

Phase 2 Terminated 214 enrolled Insmed Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.

Timeline

Start
2024-12-16
Primary completion
2026-02-12
Completion
2026-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Brensocatib Small molecule 10 mg Oral
Subject Brensocatib Small molecule 40 mg Oral